pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A clinical programs — 20 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
- Employees
- 6,080
- Programs
- 20
- Drugs
- 38
- Patents
- 0
Chiesi Farmaceutici S.p.A projects
20 ClinicalTrials.gov programs sponsored by Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici S.p.A has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CLI-05993AA3-06
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease (COPD)
1 trial -
CLI-05993AA5-06
Chiesi Farmaceutici S.p.A
Uncontrolled Asthma
1 trial -
CLI-06001AA1-04
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
1 trial -
CLI-06001AA1-05
Chiesi Farmaceutici S.p.A
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
CLI-06657AA1-01
Chiesi Farmaceutici S.p.A
Fabry's disease
1 trial -
CLI-06657AA1-03
Chiesi Farmaceutici S.p.A
Fabry disease (α-galactosidase A deficiency)
1 trial -
0.9% sodium chloride aqueous solution for IV infusion
Chiesi Farmaceutici S.p.A
Idiopathic pulmonary fibrosis (IPF)
1 trial -
CHF6001 DPI
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
CLI-05993AA9-01
Chiesi Farmaceutici S.p.A
Mild to moderate asthma
1 trial -
CLI-010073AA1-01
Chiesi Farmaceutici S.p.A
Pulmonary fibrosis
1 trial -
CLI-01535AA7-04
Chiesi Farmaceutici S.p.A
Asthma and chronic obstructive pulmonary disease (COPD).
1 trial -
CLI-01535AA9-03
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
CLI-05993BB1-01
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
CLI-06001AA1-06
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease
1 trial -
CLI-06001AA1-14
Chiesi Farmaceutici S.p.A
This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.
1 trial -
CLI-06467AC1-02
Chiesi Farmaceutici S.p.A
Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
1 trial -
CLI-06795AA1-09
Chiesi Farmaceutici S.p.A
Chronic cough
1 trial -
Cardiovascular safety assessment of Tanimilast in healthy volunteers
Chiesi Farmaceutici S.p.A
This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.
1 trial -
Not applicable
Chiesi Farmaceutici S.p.A
Non-cystic fibrosis bronchiectasis
1 trial -
CLI-05993AB1-08
Chiesi Farmaceutici S.p.A
Asthma
1 trial
Frequently asked questions
How many clinical projects does Chiesi Farmaceutici S.p.A have?
20 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.